Skip to content
Search

Latest Stories

MHRA approves Covid-19 boosters but final decision on programme still pending

Medicines and Healthcare products Regulatory Agency today (September 9) gave the go-ahead for Pfizer and AstraZeneca's Covid-19 vaccine to be used as booster shots, but said any decision to proceed with such a programme was for others to make.

The Joint Committee for Vaccination and Immunisation (JCVI) is discussing whether booster shots for the elderly and vulnerable are needed, with planning underway for a programme that could begin this month.


The final decision on whether there should be booster shots is for the government, but the regulator's decision clears one hurdle along that path.

"I am pleased to confirm that the Covid-19 vaccines made by Pfizer and AstraZeneca can be used as safe and effective booster doses," said June Raine, chief executive of the MHRA.

"It will now be for the (JCVI) to advise on whether booster jabs will be given."

Whether booster vaccinations are needed is an open question, especially as the likes of Britain and the United States are planning third doses when Covid continues to kill unvaccinated people around the world.

Pfizer has said that it believes a third shot of vaccine will be needed to maintain protection, although executives at AstraZeneca, who are not making a profit on the vaccine during the pandemic, have stressed the need to wait for evidence and not pursue booster programmes that are not needed.

Earlier on Thursday, JCVI member Adam Finn said that it wasn't clear that protection was waning against severe disease, and that a mistimed booster programme might cause more problems.

"Getting the timing right is one of several things that we need to get right. You could conceivably run into a position where you're immunising a lot of people when they don't actually need to be," he told BBC radio.

"(Then) if the vaccines do wane, then they will wane earlier than they would have done if you'd immunised them when they did need (a booster)."

More For You

NHS to roll out RSV vaccinations across 200 pharmacies in 2025/26

NHS England aims to ensure that everyone aged 75 to 79 years old is offered RSV vaccination by 31 August 2025.

Photo credit: gettyimages

RSV vaccination pilot to expand to 200 pharmacies in 2025/26

As part of its public health functions for 2025/26, NHS England plans to expand the Respiratory Syncytial Virus (RSV) immunisation programme to include up to 200 community pharmacies in targeted areas.

This follows the launch of an early adopter initiative in September 2024, where 50 community pharmacy sites in the East of England were commissioned to offer RSV vaccinations.

Keep ReadingShow less
RPS backs Pharmacist Support "Gift in Wills" initiative

The ‘Gift in Wills’ initiative is delivered in partnership with Bequeathed.

Photo credit: gettyimages

Leave a legacy: RPS partners with Pharmacist Support to promote ‘Gift in Wills’

The Royal Pharmaceutical Society (RPS) has announced its support for the ‘Gift in Wills’ initiative run by Pharmacist Support, coinciding with the charity’s birthday celebrations today (Tuesday 15 April).

This collaboration allows RPS members to create a free will while also helping to safeguard the future of vital support services for the pharmacy profession.

Keep ReadingShow less
Pharmacist Support calls for birthday donations to meet rising demand for mental health services

More and more pharmacy professionals are reaching out for help, said Danielle Hunt.

Pharmacist Support's birthday appeal: Donate to address growing mental health demand

Pharmacist Support – the independent charity dedicated to the pharmacy profession – is celebrating 184 years of service with the launch of a special birthday donations appeal.

On 15 April, the charity is urging individuals and organisations across the sector to support its campaign to raise vital funds to meet the increasing demand for its mental health and wellbeing services.

Keep ReadingShow less
Prostate cancer: At-home saliva test could save NHS £500 million annually

PRS saliva test can identify prostate cancer that was missed by an MRI scan

Photo credit: gettyimages

Prostate cancer: Spit test better than blood test in spotting men at highest risk

A simple at-home spit test could help detect prostate cancer earlier, saving the NHS around £500 million a year, according to new research published in the New England Journal of Medicine.

Funded by the National Institute for Health and Care Research (NIHR), the study found that the DNA-based saliva test was more accurate than the current prostate-specific antigen (PSA) blood test in identifying men at risk of developing prostate cancer.

Keep ReadingShow less
RPS launches innovative new learning resources for members

With RPS Learn, pharmacists can develop a new skill or improve their understanding of practice or a clinical topic.

Gettyimages

RPS launches new learning resources to boost career development for members

The Royal Pharmaceutical Society (RPS) has launched a new online learning platform designed to support the practice, development and career advancement of its members.

The new platform, called RPS Learn, offers a diverse range of bite-size learning content, available on-demand, catering to all levels — from introductory to advanced and specialist —combining new content with RPS's renowned expertise in education and training to achieve excellence for learners.

Keep ReadingShow less